· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2012 / N 2 Современные аспекты применения β-блокаторов в лечении артериальной гипертонии (список литературы) М.В. Леонова 1. Wright J.M., Musini V.M . First-line drugs for hypertension. Cohrane Database Syst.Rev. 2009 DOI: 10.1002/14651858.CD001841.pub2. 2. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665. 3. Bangalore S., Wild D., Parkar S. et al. Beta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. JACC 2008; 52: 1062-72. 4. Ghiadoni L., Bruno R.M., Stea F. et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr. Hypertens. Rep. 2009; 11(3): 190-6. 5. Agabiti-Rosei E. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment. Blood Press. 1997; 6 (suppl.2): 13-5. 6. Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. JAMA 1996; 275: 1507-13. 7. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275(19): 1507-13. 8. Jennings G., Wong J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive meta-analysis. J. Hypertens. 1998; 16 (Suppl): S29-S34. 9. Schmeider R.E., Schilachi M.P., Klingbeil A., Martus P. Update of Reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol. Dial. Transplant. 1998; 13: 564-9. 10. Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009; 54(5): 1084-91. 11. Liebson P.R., Grandits G.A., Dianzumba S. et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in thе Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706. 12. Agabiti-Rosei E., Muiesan M.L., Trimarco B. et al. Changes of LV mass and ABPM during long-term antihypertensive treatment in ELSA. J. Hypertens. 2002; 20(suppl 4):S4. Abstract. 13. Smith C., Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc.Drugs Ther. 1999; 13(2): 123-6. 14. Gosse P., Roudaut R., Herrero G., Dallocchio M. β-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: еffects on left ventricular hypertrophy. J.Cardiovas.Pharmacol. 1990; 16(Suppl 5): S145-S150. 15. Teresa E., Gonzdlez M., Camacho-Vdzquez C., Tabuenca M.J. Effects of bisoprolol on left ventricular hypertrophy in essential hypertension. Cardiovasc. Drugs Ther. 1994; 8: 837-43. 16. Laurent S., Boutouyrie P. Recent Advances in Arterial Stiffness and Wave Reflection in Human Hypertension. Hypertension 2007; 49: 1202-6. 17. Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am. J. Cardiovasc. Drugs. 2001; 1(5): 387-97. 18. Asmar R, Darne B, el Assaad M, Topouchian J. Assessment of outcomes other than systolic and diastolic blood pressure: pulse pressure, arterial stiffness and heart rate. Blood Press Monit. 2001; 6(6): 329-33. 19. Safar M.E. Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors. Curr. Opin. Nephrol. Hypertens. 2001; 10(2): 257-61. 20. Ghiadoni L., Bruno R.M., Stea F. et al. Central blood pressure, arterial stiffness, and wave reflection: new targets of treatment in essential hypertension. Curr. Hypertens. Rep. 2009; 11(3): 190-6. 21. Mahmud A., Feely J. Antihypertensive drugs and arterial stiffness. Expert Rev. Cardiovasc. Ther. 2003; 1 (1): 65-78. 22. Williams B., Lacy P.S., Thom S.M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Coundit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213-25. 23. Asmаr R. , Hugues C.H. , Pannier B. et al. Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients. Eur.Heart J. 1987; 8 (suppl M): 115-220. 24. Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am.J.Cardiol. 1991; 68(1): 61-4. 25. Deary A.J., Schumann A.L., Murfet H. et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin.Science 2002; 103: 493-9. 26. Laurent S., Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension. 2007; 49: 1202-6. 27. Tomiyama H., Tanaka H., Hashimoto H. et al. Arterial stiffness and declines in individuals with normal renal function/early chronic kidney disease. Atherosclerosis, 2010; 212(1): 345-50. 28. Blacher J., Guerin A. P., Pannier B. et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation, 1999; 99(18): 2434-9. 29. Safar M.E., London G.M, Plante G.E. Arterial stiffness and kidney function. Hypertension. 2004; 43: 163-8. 30. Pedrinelli R., Dell’omo G., Penno G. et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension. 2000; 35: 48-54. 31. Liu C.-S., Pi-Sunyer F. X., Li C.-I. et al. Albuminuria is strongly associated with arterial stiffness, especially in diabetic or hypertensive subjects - a population-based study (Taichung Community Health Study, TCHS). Atherosclerosis 2010; 211(1): 315-21. 32. Bellasi A., Ferramosca E., Ratti C. Arterial stiffness in chronic kidney disease: the usefulness of a marker of vascular damage. Int.J.Nephrol. 2011. 2011:734832. 33. Bakris G.L., Fonseca V., Katholi R.E. et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005; 46(6): 1309-15. 34. Bakris G.L., Hart P., Ritz E. Beta blockers in the management of chronic kidney disease. Kidney International 2006; 70: 1905-13. 35. Leeman M., van de Borne P., Collart F. et al. Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. J.Сardiovasс.Рharmacol. 1993; 22:785-91. 36. Paterna S., Parrinello G., Di Pasquale P. Medium-term effects of bisoprolol administration on renal hemodynamics and function in mild to moderate essential hypertension. Adv.Ther. 2007; 24(6): 1260-70. 37. Parrinello G., Paterna S., Torres D. et al. One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study. Clin. Drug Invest. 2009; 29(9): 591-600. 38. Uehara Y., Takada S., Hirawa N. et al. Vasoconstrictors and renal protection induced by beta 1-selective adrenoreceptor antagonist bisoprolol. J.Cardiovasc Pharmacol. 1994; 23(6): 897-906.    [ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]